1.31
price down icon9.03%   -0.13
after-market After Hours: 1.25 -0.06 -4.58%
loading
Xilio Therapeutics Inc stock is traded at $1.31, with a volume of 409.66K. It is down -9.03% in the last 24 hours and up +67.95% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$1.44
Open:
$1.45
24h Volume:
409.66K
Relative Volume:
1.83
Market Cap:
$59.56M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.4267
EPS:
-3.07
Net Cash Flow:
$-74.41M
1W Performance:
+32.32%
1M Performance:
+67.95%
6M Performance:
+11.02%
1Y Performance:
-45.42%
1-Day Range:
Value
$1.25
$1.45
1-Week Range:
Value
$1.035
$1.54
52-Week Range:
Value
$0.49
$2.593

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name
Name
Xilio Therapeutics Inc
Name
Phone
617-833-1027
Name
Address
828 WINTER STREET, WALTHAM
Name
Employee
73
Name
Twitter
Name
Next Earnings Date
2024-11-09
Name
Latest SEC Filings
Name
XLO's Discussions on Twitter

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-21-22 Initiated Chardan Capital Markets Buy
Jan-10-22 Initiated H.C. Wainwright Buy
Nov-16-21 Initiated Cowen Outperform
Nov-16-21 Initiated Guggenheim Buy
Nov-16-21 Initiated Morgan Stanley Overweight
Nov-16-21 Initiated Raymond James Outperform
View All

Xilio Therapeutics Inc Stock (XLO) Latest News

pulisher
Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.

Oct 30, 2024
pulisher
Oct 25, 2024

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St

Oct 25, 2024
pulisher
Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire

Oct 04, 2024
pulisher
Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian

Oct 04, 2024
pulisher
Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan

Oct 04, 2024
pulisher
Oct 02, 2024

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com

Oct 02, 2024
pulisher
Sep 23, 2024

XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa

Sep 23, 2024
pulisher
Sep 23, 2024

Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

(XFLT) Trading Signals - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information

Sep 23, 2024
pulisher
Sep 22, 2024

Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal

Sep 22, 2024
pulisher
Sep 21, 2024

XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World

Sep 20, 2024
pulisher
Sep 14, 2024

Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India

Sep 14, 2024
pulisher
Sep 14, 2024

Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Sep 14, 2024
pulisher
Sep 05, 2024

XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily

Sep 05, 2024
pulisher
Sep 02, 2024

Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex

Sep 02, 2024
pulisher
Aug 28, 2024

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire

Aug 28, 2024
pulisher
Aug 20, 2024

Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com

Aug 20, 2024
pulisher
Aug 20, 2024

Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada

Aug 20, 2024
pulisher
Aug 08, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire

Aug 08, 2024
pulisher
Jul 31, 2024

Understanding the Risks of Investing in Xilio Therapeutics Inc (XLO) - Knox Daily

Jul 31, 2024
pulisher
Jul 28, 2024

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

Jul 28, 2024
pulisher
Jul 12, 2024

Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Simply Wall St

Jul 12, 2024
pulisher
Jul 06, 2024

Head to Head Analysis: Indivior (NASDAQ:INDV) versus Xilio Therapeutics (NASDAQ:XLO) - Defense World

Jul 06, 2024
pulisher
Jun 29, 2024

Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth? - Yahoo Finance

Jun 29, 2024
pulisher
Jun 28, 2024

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 83.1% - Defense World

Jun 28, 2024
pulisher
Jun 25, 2024

$82 million series A round propels Exsilio into gene editing race - The Pharma Letter

Jun 25, 2024
pulisher
Jun 22, 2024

Head to Head Analysis: Xilio Therapeutics (NASDAQ:XLO) versus VBI Vaccines (NASDAQ:VBIV) - Defense World

Jun 22, 2024
pulisher
Jun 21, 2024

Biopharma Layoff Tracker 2024: Ginkgo, Cara, Barinthus and More Cut Staff - BioSpace

Jun 21, 2024
pulisher
Jun 19, 2024

Xilio Therapeutics Inc (XLO) stock analysis: A comprehensive overview – US Post News - US Post News

Jun 19, 2024
pulisher
Jun 19, 2024

Investing in Xilio Therapeutics Inc (XLO): What You Must Know – Knox Daily - Knox Daily

Jun 19, 2024
pulisher
Jun 19, 2024

Xilio Therapeutics Inc (XLO)'s Market Momentum: Closing Strong at 0.95, Down -0.33 – DWinneX - The Dwinnex

Jun 19, 2024
pulisher
Jun 15, 2024

Xilio Therapeutics, Inc. (NASDAQ:XLO) Shares Sold by Octagon Capital Advisors LP - Defense World

Jun 15, 2024
pulisher
Jun 14, 2024

Xilio Therapeutics expands board with industry experts - Investing.com India

Jun 14, 2024
pulisher
Jun 14, 2024

Xilio Therapeutics expands board with industry experts By Investing.com - Investing.com

Jun 14, 2024
pulisher
Jun 13, 2024

Xilio Therapeutics Enhances Board with Two New DirectorsTipRanks.com - TipRanks

Jun 13, 2024
pulisher
Jun 13, 2024

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com

Jun 13, 2024
pulisher
Jun 10, 2024

Was there any good news for Xilio Therapeutics Inc (XLO) stock in the last session? – US Post News - US Post News

Jun 10, 2024
pulisher
Jun 10, 2024

Monitoring Xilio Therapeutics Inc (XLO) after recent insider movements – Knox Daily - Knox Daily

Jun 10, 2024
pulisher
Jun 04, 2024

Xilio Therapeutics (NASDAQ:XLO) Trading Down 2.8% - Defense World

Jun 04, 2024
pulisher
May 29, 2024

Xilio Therapeutics Inc (XLO) Stock: A Year of Decreases and Increases - The InvestChronicle

May 29, 2024
pulisher
May 29, 2024

Gilead and Cartography enter deal to develop cancer therapies - Yahoo Finance

May 29, 2024
pulisher
May 27, 2024

Market Recap: Xilio Therapeutics Inc (XLO)'s Negative Momentum, Closing at 1.05 – DWinneX - The Dwinnex

May 27, 2024

Xilio Therapeutics Inc Stock (XLO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):